View Press Releases
Advancing regenerative medicine: Cellbricks Therapeutics reaches key milestone using Rousselot biomaterials
A key hurdle in regenerative medicine is achieving transplanted cell survival and integration with host tissues while minimizing immune responses. To address this, Cellbricks incorporated Rousselot’s medical-grade biomaterials – specifically, purified gelatins – which played a pivotal role in enhancing both the structural and functional performance of the bioink used in the constructs.
"The purity, consistency and biocompatibility of Rousselot gelatin were key to the success of our project,” said Alexander Thomas, Soft Tissue Program Leader at Cellbricks. “We observed rapid tissue integration and vascularization that led to the formation of viable fatty tissue in the constructs– key indicators of successful long-term grafting.”
Tanja Vervust, Global Director Biomedical at Rousselot, added “Cellbricks’ pioneering work in organ and tissue printing, combined with Rousselot’s high-quality biomaterials, can represent a significant step forward in regenerative medicine. This achievement reflects how collaboration around medical-grade biomaterials and advanced bioprinting can accelerate progress in tissue engineering, delivery of cell therapies, and organ printing.”
Rousselot continues to play a key role in advancing regenerative therapies by providing innovators like Cellbricks with high-performance biomaterials that enable new possibilities in the field.
ENDS
For further information, please contact:
Rousselot
Caroline Brochard-Garnier, Director Communications & PR
E: caroline.brochard-garnier@rousselot.com
Cellbricks Therapeutics
Moritz Marschall, Founder's Associate
Sciad Communications, Media Relations
Sophie Protheroe, Account Director
T: +44 2034 057892
Notes for Editors
About Rousselot
Rousselot, the health brand of Darling Ingredients, is the global leader in gelatin- and collagen-based solutions for the food, health & nutrition, biomedical and pharmaceutical industries. Working in partnership with our global customer base, we deliver advanced ingredient solutions that enable innovation, excite today's consumers, and contribute to public health. Through our state-of-the-art operations, extensive technical expertise and sustained scientific research, we help our customers achieve their goals and create world-class products, and we “Reach further together.”
About Cellbricks Therapeutics
Cellbricks Therapeutics is a Berlin-based biotech company pioneering the future of regenerative medicine and longevity. Built on deep tech innovation, the company combines proprietary 3D-bioprinting technology with advanced biomaterials and human cells to develop implantable tissue grafts for clinical use. Cellbricks’ mission is to transform healthcare by restoring organ function and replacing damaged tissue with living, functional implants – produced reliably and at scale.